CAPITAL STOCK (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
May 08, 2025 |
Jun. 06, 2023 |
Jun. 25, 2025 |
May 23, 2025 |
Dec. 31, 2024 |
Sep. 30, 2021 |
Jul. 31, 2025 |
Jul. 31, 2025 |
Jul. 31, 2024 |
Feb. 02, 2025 |
|
| Class of Stock [Line Items] | ||||||||||
| Share Price | $ 0.001 | $ 0.001 | ||||||||
| Stock-based compensation expense | $ 3,937,000 | $ 2,751,000 | ||||||||
| BioLumina, LLC [Member] | ||||||||||
| Class of Stock [Line Items] | ||||||||||
| Number of restricted shares acquired | 30,000 | |||||||||
| Value of restricted shares acquired | $ 58,000 | |||||||||
| Restricted Stock Awards [Member] | ||||||||||
| Class of Stock [Line Items] | ||||||||||
| Grant of unvested restricted common stock | 40,000 | |||||||||
| Fair value of the shares as of the date of grant | 104,000 | |||||||||
| Stock-based compensation expense | 104,000 | |||||||||
| Unamortized compensation | $ 554,000 | 554,000 | ||||||||
| Unvested Stock Grants [Member] | ||||||||||
| Class of Stock [Line Items] | ||||||||||
| Stock-based compensation expense | $ 22,000 | $ 75,000 | ||||||||
| 2021 Plan [Member] | ||||||||||
| Class of Stock [Line Items] | ||||||||||
| Maximum aggregate number of shares | 2,500,000 | 1,250,000 | ||||||||
| Number of shares, outstanding | 1,620,482 | 1,620,482 | ||||||||
| Future issuance | 1,218,647 | 1,218,647 | ||||||||
| Settlement Agreement [Member] | Series C Preferred Shares [Member] | ||||||||||
| Class of Stock [Line Items] | ||||||||||
| Shares transferred | 50 | |||||||||
| Consulting Agreement [Member] | Consultant [Member] | ||||||||||
| Class of Stock [Line Items] | ||||||||||
| Fair value of the shares as of the date of grant | $ 1,428,000 | |||||||||
| Stock-based compensation expense | $ 1,428,000 | |||||||||
| Grant of unvested restricted common stock description | In connection with the Consultant Agreement, the Company granted the Consultant 100,000 shares of common stock (“Shares”) and warrants to purchase an additional 500,000 shares of common stock (the “Warrants”). 50,000 of the Shares vested upon execution of the Consulting Agreement and the remaining 50% will vest on the six-month anniversary of the Consulting Agreement. The fair value of the Shares as of the date of grant was $286,000. The Company will amortize the $286,000 of stock-based compensation expense over the term of the Consulting Agreement. The Company amortized $48,000 of expense for the three-months and nine months ended July 31, 2025. The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable on the terms provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. | |||||||||
| Consulting Agreement [Member] | Second Consultant [Member] | ||||||||||
| Class of Stock [Line Items] | ||||||||||
| Fair value of the shares as of the date of grant | $ 82,000 | |||||||||
| Stock-based compensation expense | $ 82,000 | |||||||||
| Grant of unvested restricted common stock description | in connection with an agreement with a second consultant (“Second Consultant”), the Company agreed to grant the Second Consultant 40,000 shares of the Company’s common stock which shall vest quarterly over a 2-year period commencing on the date that sales obtained by the Company from customers introduced by Second Consultant exceed $400,000 (“Milestone”) and provided that the Milestone is achieved by December 31, 2025. Upon termination of the agreement for any reason, any unvested stock shall be forfeited. In addition, the Second Consultant will be entitled to receive commissions on sales of the Company’s products to customers introduced by the Representative in the form of cash and common stock of the Company based on sales milestones. The agreement may be terminated by the Company at any time by either party upon 30 days written notice. | |||||||||